# OnCo record bemarituzumab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/bemarituzumab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "bemarituzumab" ;
  schema:name "Bemarituzumab"@en ;
  schema:description "Bemarituzumab is an antibody against FGFR2b, a growth receptor overproduced in about a third of stomach cancers. It improved survival early in its phase 3 trial, but the gain faded with longer follow-up."@en ;
  schema:url <https://onco.cc/drugs/bemarituzumab/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://www.amgen.com/newsroom/press-releases/2025/06/amgen-announces-positive-topline-phase-3-results-for-bemarituzumab-in-fibroblast-growth-factor-receptor-2b-fgfr2b-positive-firstline-gastric-cancer> ;
  onco:status "phase-3" ;
  onco:modality "Monoclonal antibody (anti-FGFR2b)" ;
  onco:cancers <https://onco.cc/cancers/gastric/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/fgfr2/> ;
  onco:companies <https://onco.cc/companies/amgen/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/> ;
  onco:trials <https://onco.cc/trials/fortitude-101/> .